Showing results (21-30 of 30) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Diabetes, Obesity & Metabolism|March 5, 2019
Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS AsiaLinong Ji, Yanmei Liu, Heng Miao, et al.Diabetes, Obesity & Metabolism|December 22, 2017
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trialRichard E Pratley, Roy Eldor, Annaswamy Raji, et al.Diabetes, Obesity & Metabolism|September 19, 2017
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized studySamuel Dagogo-Jack, Jie Liu, Roy Eldor, et al.Diabetes, Obesity & Metabolism|September 16, 2025
Combined agonism of nutrient receptors GPR40 and GPR119 with K-757 and K-833 results in weight loss and blood pressure reductions in obese subjects without type 2 diabetes mellitusMichael Crutchlow, Jiajun Liu, Christopher Romero, et al.American Heart Journal|October 6, 2018
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)Christopher P Cannon, Darren K McGuire, Richard Pratley, et al.Journal of Clinical Pharmacology|May 1, 2014
Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapibBrett Lauring, Xiujiang Susie Li, Yang Liu, et al.Cell Metabolism|December 3, 2025
Gut enteroendocrine cell activation using a combination of GPR119 and GPR40 agonists results in synergistic hormone secretion in mice and humansIyassu K Sebhat, Monika J M Murphy, Shuqin Zheng, et al.Journal of Medicinal Chemistry|July 25, 2025
Discovery of Gut-Targeted GPR40 Agonist K-757 and GPR119 Agonist K-833, a Combination Treatment for Metabolic DisordersChristopher R Moyes, Shuwen He, Simon Mathieu, et al.Journal of Medicinal Chemistry|March 23, 2012
(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humansP Douglas Boatman, Brett Lauring, Thomas O Schrader, et al.Science Translational Medicine|August 24, 2012
Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppressionBrett Lauring, Andrew K P Taggart, James R Tata, et al.Pageof 3